Scientific article
Comment
A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab
Published inLancet. Infectious diseases, vol. 22, no. 9, 1278
Publication date2022-09
First online date2022-07-18
Keywords
- Antibodies, Monoclonal
- Antibodies, Neutralizing
- Antibodies, Viral
- Humans
Affiliation entities
Research groups
Funding
- Gilead Sciences
- Merck
- ViiV Healthcare
- AbbVie
Citation (ISO format)
HENTZIEN, Maxime et al. A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab. In: Lancet. Infectious diseases, 2022, vol. 22, n° 9, p. 1278. doi: 10.1016/S1473-3099(22)00495-9
Main files (1)
Article (Published version)
Identifiers
- PID : unige:167165
- DOI : 10.1016/S1473-3099(22)00495-9
- PMID : 35863364
- PMCID : PMC9292633
Additional URL for this publicationhttps://www.sciencedirect.com/science/article/pii/S1473309922004959
Journal ISSN1473-3099
